#India #Mumbai #Lupin Limited #YUVEZZI #Tenpoint Therapeutics

Strategic Partnership to Enhance Eye Care

In a significant move aimed at expanding access to innovative healthcare solutions, Lupin Limited, a leading global pharmaceutical company, has formed a strategic partnership with Tenpoint Therapeutics. This collaboration focuses on the commercialization of YUVEZZI™, an eye drop formulation designed to treat presbyopia, in key European territories including the EU, UK, Switzerland, Norway, and Iceland.

Partnership Details

The partnership centers around VISUfarma B.V., a wholly-owned subsidiary of Lupin, which has secured exclusive licensing rights for the regulatory activities, marketing, distribution, and sales of YUVEZZI™ in the specified territories. This product is noteworthy as it is the first dual-active ingredient eye drop approved for treating presbyopia, a condition that typically affects individuals over the age of 40, leading to difficulty in focusing on near objects.

Henric Bjarke, CEO of Tenpoint, expressed excitement about the partnership, stating, "This collaboration represents a pivotal moment as we strive to make YUVEZZI™ available for the millions affected by presbyopia and eye care professionals globally." The arrangement allows for strategic investments from VISUfarma into Tenpoint’s operations, along with payments tied to regulatory milestones, market entries, and sales royalties.

About YUVEZZI™

YUVEZZI™ is formulated with 2.75% carbachol and 0.1% brimonidine, working together to enhance near vision. Carbachol aids in constricting the pupils, while brimonidine helps prevent excessive dilation, effectively improving visual clarity for patients.

The product is considered a significant advancement in ophthalmic treatment, especially appealing to the rapidly expanding aging population. This is evident since approximately 128 million people in the U.S. and around 2 billion worldwide suffer from presbyopia.

Lupin's Vision

Vinita Gupta, CEO of Lupin, emphasized the company’s continuing commitment to specialized care: "We are delighted to collaborate with Tenpoint Therapeutics to introduce a novel ophthalmic treatment as part of our specialized healthcare strategy." The partnership follows Lupin’s strategic acquisition of VISUfarma, enhancing its eye care segment and reinforcing its presence in the competitive European markets.

The initiative not only focuses on expanding product availability but also aims to improve patient outcomes and consolidate Lupin's leading position in the ophthalmic sector across licensed territories.

Future Outlook

Tenpoint Therapeutics is actively pursuing the U.S. market as well, following recent FDA approval for YUVEZZI™. They are also working on submitting market authorization applications for YUVEZZI™ in other critical regions globally, further extending its reach beyond Europe. This embodies a robust strategy for both companies to address unmet patient needs in eye care, delivering innovative solutions that target pressing health issues.

As this collaboration takes shape, Lupin and Tenpoint Therapeutics are expected to make notable strides in enhancing the delivery of eye care treatments, with YUVEZZI™ as a cornerstone of their efforts.